Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | SETD7 | Q8WTS6 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | NAMPT | P43490 | 1/20 | 0.49 |
| ▸ | THRA | P10827 | 1/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.49 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.48 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.48 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.48 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.48 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | ACHE | P22303 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL15845932 | 0.98 | ALDH1A1 (0.58) | ALDH1A1SETD7HPGDSMN1; SMN2HTT | |
| SCHEMBL1367341 | 0.91 | HPGD (0.65) | ALDH1A1HPGDSMN1; SMN2HTTNAMPT | |
| SCHEMBL30046741 | 0.88 | ALDH1A1 (0.73) | ALDH1A1SETD7HPGDSMN1; SMN2HTT | |
| SCHEMBL6350121 | 0.84 | LMNA (0.68) | ALDH1A1SMN1; SMN2NAMPTTHRBHDAC4 | |
| SCHEMBL25231901 | 0.84 | TRPV1 (0.57) | ALDH1A1TRPV1MAPK1LMNATSHR | |
| Hydrochloric Acid SCHEMBL1367735 | 0.83 | LMNA (0.69) | ALDH1A1SMN1; SMN2THRBHDAC4HDAC1 | |
| SCHEMBL875451 | 0.82 | ALDH1A1 (0.53) | ALDH1A1SMN1; SMN2HTTUSP2MAPK1 | |
| SCHEMBL2316651 | 0.81 | KDM4E (0.57) | ALDH1A1TRPV1KMT2A | |
| SCHEMBL11407954 | 0.81 | ALDH1A1 (0.65) | ALDH1A1SETD7HPGDSMN1; SMN2HTT | |
| SCHEMBL6207528 | 0.81 | SMN1; SMN2 (0.67) | ALDH1A1SETD7HPGDSMN1; SMN2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 121 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12012466-B2 | Peptide macrocycles against Acinetobacter baumannii | HOFFMANN-LA ROCHE INC. (US) | 2024-06-18 | — | — | US | disclosed |
| US-11787783-B2 | Heparanase inhibitors and use thereof | Beta Therapeutics Pty Ltd (AU) | 2023-10-17 | — | — | US | disclosed |
| US-11787783-B2 | Heparanase inhibitors and use thereof | Beta Therapeutics Pty Ltd (AU) | 2023-10-17 | — | — | US | disclosed |
| US-11787783-B2 | Heparanase inhibitors and use thereof | Beta Therapeutics Pty Ltd (AU) | 2023-10-17 | — | — | US | disclosed |
| US-20220411468-A1 | PEPTIDE MACROCYCLES AGAINST ACINETOBACTER BAUMANNII | HOFFMANN-LA ROCHE INC. (US) | 2022-12-29 | — | — | US | disclosed |
| EP-3398598-B1 | SULFONAMIDE DERIVATIVE AND PREPARATION METHOD AND USE THEREOF | HITGEN INC (CN) | 2022-04-06 | — | — | EP | disclosed |
| US-11225655-B2 | Bi-functional complexes and methods for making and using such complexes | NUEVOLUTION A/S (DK) | 2022-01-18 | — | — | US | disclosed |
| CN-108350028-B | Peptide macrocycles against Acinetobacter baumannii | 豪夫迈·罗氏有限公司 | 2021-12-07 | — | — | CN | disclosed |
| US-11149008-B2 | Sulfamide derivatives and preparation method and use thereof | HitGen, Inc. | 2021-10-19 | — | — | US | disclosed |
| CN-107501099-B | Modulators of ATP-binding cassette transporters | 沃泰克斯药物股份有限公司 | 2021-03-19 | — | — | CN | disclosed |
| EP-1979353-A2 | FUSED HETEROBICYCLIC KINASE INHIBITORS | OSI Pharmaceuticals, Inc. (US) | 2008-10-15 | — | — | EP | disclosed |
| EP-1974212-A1 | COMPOUNDS USEFUL IN CFTR ASSAYS AND METHODS THEREWITH | Vertex Pharmaceuticals Incorporated (US) | 2008-10-01 | — | — | EP | disclosed |
| US-20080103141-A1 | New compounds | BIOVITRUM (SE) | 2008-05-01 | — | — | US | disclosed |
| US-20080071095-A1 | Cystic fibrosis transmembrane conductance | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-03-20 | — | — | US | disclosed |
| WO-2008009077-A2 | 4,6-DL- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2008-01-24 | — | — | WO | disclosed |
| WO-2008009077-A2 | 4,6-DL- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2008-01-24 | — | — | WO | disclosed |
| US-20070208053-A1 | Fused heterobicyclic kinase inhibitors | OSI PHARMACEUTICALS, INC. | 2007-09-06 | — | — | US | disclosed |
| WO-2007084667-A2 | FUSED HETEROBICYCLIC KINASE INHIBITORS | OSI PHARMACEUTICAL, INC. (US) | 2007-07-26 | — | — | WO | disclosed |
| WO-2007075946-A1 | COMPOUNDS USEFUL IN CFTR ASSAYS AND METHODS THEREWITH | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-07-05 | — | — | WO | disclosed |
| US-20060074075-A1 | including cystic fibrosis transmembrane conductance regulator (\"CFTR\"), used for treating genetic disorders; respiratory system disorders | VERTEX PHARMACEUTICALS INCORPORATED | 2006-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220411468-A1 | PEPTIDE MACROCYCLES AGAINST ACINETOBACTER BAUMANNII | VIP, ARG1, CX3CR1 | ALDH1A1 4290/4885SETD7 2915/4885HPGD 4181/4885 |
| US-12012466-B2 | Peptide macrocycles against Acinetobacter baumannii | VIP, ARG1, CX3CR1 | ALDH1A1 4290/4885SETD7 2915/4885HPGD 4181/4885 |
| US-20080103141-A1 | New compounds | GPR119, GPR3, GPR4 | ALDH1A1 1823/4885SETD7 4692/4885HPGD 1957/4885 |
| US-11149008-B2 | Sulfamide derivatives and preparation method and use thereof | HDAC6, HDAC1, HDAC11 | ALDH1A1 554/4885SETD7 38/4885HPGD 429/4885 |
| US-11787783-B2 | Heparanase inhibitors and use thereof | HPSE, HEXD, ENGASE | ALDH1A1 1394/4885SETD7 4687/4885HPGD 246/4885 |
| US-20080071095-A1 | Cystic fibrosis transmembrane conductance | CFTR, ABCB1, ABCC1 | ALDH1A1 2651/4885SETD7 4724/4885HPGD 1487/4885 |
| US-20060074075-A1 | including cystic fibrosis transmembrane conductance regulator (\"CFTR\"), used for treating genetic disorders; respiratory system disorders | CFTR, ABCC4, ABCC2 | ALDH1A1 2221/4885SETD7 4809/4885HPGD 1132/4885 |
| US-20070208053-A1 | Fused heterobicyclic kinase inhibitors | MAP2K5, MAP2K7, MAP2K2 | ALDH1A1 4769/4885SETD7 2001/4885HPGD 3305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.